general news

Humanigen Partners with Lonza to Expand Lenzilumab Production Capacity

Humanigen Partners with Lonza to Expand Lenzilumab Production Capacity
Humanigen Partners with Lonza to Expand Lenzilumab Production Capacity

Humanigen announced a collaboration with Lonza to extend the manufacturing capacity for lenzilumab which is presently in Phase 3 clinical trials for COVID-19 for possible Emergency Use Authorization in 2020 and successive distribution. Humanigen is a biopharmaceutical company that focuses on treating and preventing an immune hyper-response named ‘cytokine storm’.

With this collaboration, Humanigen can leverage monoclonal antibody production and monitoring expertise. Lenzilumab demonstrates Humanigen's patented Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal immunoglobulin that has the potential to treat and prevent cytokine storm, which can activate the acute respiratory distress syndrome in critical COVID-19 cases.

Humanigen gets the extra capacity of cGMP manufacturing of lenzilumab with operations expected to start at the beginning of 2021. The lenzilumab production will commence at Lonza's 2,000L manufacturing facilities at Hayward, USA. Technology transmission is anticipated to begin in Q3 2020.

Humanigen, Inc. is developing a range of pre-clinical and clinical therapies. For cancer treatments and infectious diseases through the novel, state-of-the-art GM-CSF neutralization, and gene-knockout platforms. Gene-editing and GM-CSF neutralization platform technologies are believed to have the ability to decrease the inflammatory cascade related to coronavirus infection. The company’s primary focus is to prevent or reduce the cytokine release syndrome that heads severe lung dysfunction and ARDS in critical SARS-CoV-2 infection cases.

The firm aims to create advanced combinatory gene-edited CAR-T therapies using strategies to increase efficiency while utilizing gene knockout technologies to control toxicity. The company is also developing its range of patented first-in-class EphA3-CAR-T for numerous EMR1-CAR-T for various eosinophilic disorders and solid cancers. It is also discovering the efficiency of its GM-CSF neutralization technologies with other CAR-T, natural or bispecific killer (NK) T cells engaging immunotherapy treatments to breakdown the efficiency linkage, including to treat or prevent graft-versus-host disease in patients going through allogeneic hematopoietic stem cell transplantation.



About the author

Bhushan Tambe

A qualified computer graduate, Bhushan Tambe always nurtured a passion for words. Post his education, he decided to transform his penchant of penning down poetry and stories into a full-time career. Presently, Bhushan writes numerous articles for and a few other websites, on subjects spanning business, finance, and the like.